相关实验视频
Updated: Jan 13, 2026

05:44
Formation of Dispersible Taohong Siwu Tablets
Published on: February 3, 2023
2.0K
[组合药物输送系统的构建和应用,结合液体自微乳化和固体分散微粒片用于坦辛成分]
Xiao-Yan Ma1, Jiang-Dong Dai1, Shu-Qi Hu2
1Jianhu County People's Hospital Yancheng 224700, China.
概括
这项研究开发了一种新的tanshinone成分 (TSC) 自微乳化分散微片的复合系统. 这种方法显著提高了TSC的溶解性和生物可用性,为药物输送提供了新的策略.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 材料科学 材料科学 材料科学
背景情况:
- 坦辛成分 (TSC) 的低水溶性阻碍了它们的治疗效果和质量.
- 开发稳定和有效的药物输送系统对于难以溶解的化合物至关重要.
研究的目的:
- 创建一个创新的复合物药物加载系统,用于TSC使用自微乳化分散微片.
- 改善TSC.的可溶性,稳定性和体外释放.
主要方法:
- 建立了一个通过响应表面方法优化的三元自我微乳液系统 (乙烯酸盐,聚氧乙烯麻油,绝对乙醇).
- 配制和特征分散的微粒片,包括自我微乳液.
- 评估TSC溶解性,稳定性,体外药物释放,并使用各种分析技术 (FTIR,XRD,DSC) 进行复合系统的特征化.
主要成果:
- 优化的自我微乳化增加了TSC平衡溶解度,达到58.65 mg·mL-1的优异稳定性.
- 复合材料微片表现出良好的机械性能,快速分散,并保持了自我微乳液结构.
- 试验室研究显示,在HCl介质中,TSC在48小时内完全释放,这表明生物可用性提高.
结论:
- 一个新的"液体自我微乳化-固体分散微平板电脑"复合系统已成功为TSC开发.
- 该系统有效地克服了TSC的可溶性限制,为提高其生物可访问性提供了一个有希望的方法.
- 为了获得最佳的结果,建议对生产过程中温度控制进行进一步的研究.
相关概念视频
Bioavailability Enhancement: Drug Permeability Enhancement
183
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
183
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
193
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
193
Bioavailability Enhancement: Drug Solubility Enhancement
212
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
212
Factors Influencing Drug Absorption: Pharmaceutical Parameters
392
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
392
Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.6K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.6K
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
298
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
298

